We apply all the main and supporting principles of good corporate governance in the UK Corporate Governance Code (formerly the Combined Code) and related guidance.
As a foreign issuer with American Depositary Shares listed on the New York Stock Exchange (NYSE), we must also disclose any significant ways in which our corporate governance practices differ from those followed by US companies under the NYSE’s corporate governance listing standards.
Detailed information concerning our performance in regard to corporate governance can be found in the corporate governance section of our latest Annual Report.
Information on our corporate governance performance in preceding years can be found in our previous Annual Reports.
We have a highly experienced Board and Senior Executive Team. The Board is responsible for the Group's corporate governance, sets the Group's strategy and policies, has overall responsibility for the oversight of risk and also monitors progress towards meeting its strategic objectives and annual plans. The Board discharges these responsibilities through a programme of meetings that includes a formal, annual strategy review. The Board also assesses whether or not, and to what extent, its obligations to the Company's shareholders and other stakeholders are understood and met. This includes regular reviews of the Group's financial performance and critical business issues.
More information on the principle roles and responsibilities of our Board can be found in the corporate governance section of our latest Annual Report.
The terms and conditions of appointment of Non-Executive Directors are available to view and download here:
Board Committee remits
The remits for AstraZeneca's Board Committees are available to view/download here:
AstraZeneca’s independent external auditor is elected each year by the shareholders at the Annual General Meeting.
At present our auditors are KPMG LLP.
8 Salisbury Square
Articles of Association
Share option plans for employees